Edition:
United States

Verastem Inc (VSTM.OQ)

VSTM.OQ on NASDAQ Stock Exchange Global Market

7.66USD
22 Jun 2018
Change (% chg)

$-0.00 (-0.00%)
Prev Close
$7.66
Open
$7.70
Day's High
$7.77
Day's Low
$7.27
Volume
5,774,334
Avg. Vol
319,044
52-wk High
$9.07
52-wk Low
$2.06

Select another date:

Wed, May 16 2018

BRIEF-Verastem Oncology Announces Public Offering Of Common Stock

* VERASTEM ONCOLOGY ANNOUNCES PUBLIC OFFERING OF COMMON STOCK

BRIEF-Verastem Oncology Reports Q1 Loss Per Share Of $0.41

* VERASTEM ONCOLOGY REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS

BRIEF-Verastem Reports Year-End 2017 Financial Results

* VERASTEM - EXPECTS TO HAVE SUFFICIENT CASH, CASH EQUIVALENTS AND INVESTMENTS TO FUND CURRENT OPERATING PLAN AND CAPEX REQUIREMENTS INTO H2 2018 Source text for Eikon: Further company coverage:

BRIEF-Verastem Submits Marketing Application To FDA For Duvelisib

* VERASTEM SUBMITS NEW DRUG APPLICATION TO U.S. FDA FOR DUVELISIB FOR THE TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA AND FOLLICULAR LYMPHOMA

BRIEF-Verastem Presents Preclinical Data Highlighting The Effects Of Duvelisib In Combination With Immune Checkpoint Or Co-Stimulatory Antibodies In B Cell Lymphoma Model

* VERASTEM PRESENTS PRECLINICAL DATA AT ASCO-SITC HIGHLIGHTING THE SYNERGISTIC EFFECTS OF DUVELISIB IN COMBINATION WITH IMMUNE CHECKPOINT OR CO-STIMULATORY ANTIBODIES IN B CELL LYMPHOMA MODEL

BRIEF-Verastem Announces Increased Hercules Debt Facility

* VERASTEM INC - ANNOUNCED ENTRY INTO AN AMENDMENT TO ITS LOAN AND SECURITY AGREEMENT WITH HERCULES CAPITAL INC

Select another date: